Co- infección VIH y Tuberculosis - UPCH

- 20 -
19. Warren RM, Van Helden PD. HIV-1 and tuberculosis infection. Lancet
2002; 359:1619–1620.
20.- Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing
tuberculosis in non-HIV-infected persons (Cochrane Review). The Cochrane
Library, Issue 2, Oxford, 2002.
21.- Quigley MA, Mwinga A, Hosp M et al. Long-term effect of preventive
therapy for tuberculosis in a cohort of HIVinfected Zambian adults. AIDS
2001; 15: 215–222.
22.- Gordin F, Chaisson RE, Matts JP et al. Rifampicin and pyrazinamide
versus isoniazid for prevention of tuberculosis in HIV-infected persons: an
international randomized trial. J Am Med Assoc 2000; 283: 1445–1450.
23.-Sonnerberg P, Murray J, Glynn JR, Shewer S, Kambashi B, Godfrey-
Faussett P. HIV-1 and recurrence, relapse and reinfection of tuberculosis
after cure: a cohort study in South African mineworkers. Lancet 2001; 358:
1687–1693.
24.- Fitzgerald D, Desvarieux M, Severe P, Joseph P, Johnson W, Pape J.
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in
HIV-1-infected individuals: a randomized trial. Lancet 2000; 356: 1470–
1474.
Uso de antirretrovirales. Instituto de Medicina Tropical “AvH”.Facultad de Medicina. Universidad Peruana Cayetano Heredia.
TELEMEDICINA